Monocytes as immune targets in arterial hypertension.
Philip WenzelPublished in: British journal of pharmacology (2018)
The role of myelomonocytic cells appears to be critical for the initiation, progression and manifestation of arterial hypertension. Monocytes can induce vascular inflammation as well as tissue remodelling and (mal)adaptation by secreting chemokines and cytokines, producing ROS, expressing coagulation factors and transforming into macrophages. A multitude of adhesion molecules promote the infiltration and accumulation of monocytes into the kidney, heart, brain and vasculature in hypertension. All these facets offer the possibility to pharmacologically target monocytes and may represent novel therapeutic ways to treat hypertension, attenuate hypertension-associated end organ damage or prevent the development or worsening of high blood pressure. LINKED ARTICLES: This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc.
Keyphrases
- arterial hypertension
- blood pressure
- hypertensive patients
- dendritic cells
- peripheral blood
- heart rate
- oxidative stress
- heart failure
- cell death
- type diabetes
- cell cycle arrest
- white matter
- resting state
- multiple sclerosis
- escherichia coli
- functional connectivity
- insulin resistance
- adipose tissue
- cell proliferation
- atrial fibrillation
- brain injury